Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

Targeted but not trouble-free: efalizumab and PML

Nature Reviews Rheumatology volume 5, pages 418–419 (2009)Cite this article

In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in patients undergoing immunosuppressive therapy for chronic inflammatory disorders.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. US Food and Drug Administration FDA public health advisory: updated safety information about Raptiva (efalizumab) [online] (2009).

  2. US Food and Drug Administration FDA approves updated labeling for psoriasis drug Raptiva: safety concerns drove labeling change [online] (2009).

  3. Calabrese, L. H., Molloy, E. S., Huang, D. & Ransohoff, R. M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 56, 2116–2128 (2007).

    Article  PubMed  Google Scholar 

  4. Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun. Rev. 8, 144–146 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. Calabrese, L. H. & Molloy, E. S. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis. 67 (Suppl. 3), iii64–iii65 (2008).

    PubMed  Google Scholar 

  6. Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy—a national estimate of frequency in SLE and other rheumatic diseases. Arthritis Rheum. 58, S637 (2008).

    Article  Google Scholar 

  7. Ransohoff, R. M. Natalizumab and PML. Nat. Neurosci. 8, 1275 (2005).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic, Cleveland, OH, USA

    Eamonn S. Molloy & Leonard H. Calabrese

Authors
  1. Eamonn S. Molloy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonard H. Calabrese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eamonn S. Molloy.

Ethics declarations

Competing interests

E. S. Molloy declares no competing interests. L. H. Calabrese has acted as a consultant for the following companies: Genentech, Wyeth, Biogen and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molloy, E., Calabrese, L. Targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol 5, 418–419 (2009). https://doi.org/10.1038/nrrheum.2009.142

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.142

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing